Carcinoid syndrome classification: Difference between revisions
Jump to navigation
Jump to search
| Line 12: | Line 12: | ||
*[[GET]]-[[NET]]s produce a number of [[secretory]] products, resulting in a wide range of clinical symptoms.<ref name="pmid29260133">{{cite journal |vauthors=Büyükaşık K, Arı A, Tatar C, Akçe B, Sevinç MM, Sarı S, Paşaoğlu E, Bektaş H |title=Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases |journal=Turk J Surg |volume=33 |issue=4 |pages=279–283 |date=2017 |pmid=29260133 |doi=10.5152/UCD.2017.3685 |url=}}</ref> <ref name="pmid26911175">{{cite journal |vauthors=Davies L, Weickert MO |title=Gastroenteropancreatic neuroendocrine tumours: an overview |journal=Br J Nurs |volume=25 |issue=4 |pages=S12–5 |date=2016 |pmid=26911175 |doi=10.12968/bjon.2016.25.4.S12 |url=}}</ref><ref name="pmid21311954">{{cite journal |vauthors=Oberg K, Castellano D |title=Current knowledge on diagnosis and staging of neuroendocrine tumors |journal=Cancer Metastasis Rev. |volume=30 Suppl 1 |issue= |pages=3–7 |date=March 2011 |pmid=21311954 |doi=10.1007/s10555-011-9292-1 |url=}}</ref> | *[[GET]]-[[NET]]s produce a number of [[secretory]] products, resulting in a wide range of clinical symptoms.<ref name="pmid29260133">{{cite journal |vauthors=Büyükaşık K, Arı A, Tatar C, Akçe B, Sevinç MM, Sarı S, Paşaoğlu E, Bektaş H |title=Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases |journal=Turk J Surg |volume=33 |issue=4 |pages=279–283 |date=2017 |pmid=29260133 |doi=10.5152/UCD.2017.3685 |url=}}</ref> <ref name="pmid26911175">{{cite journal |vauthors=Davies L, Weickert MO |title=Gastroenteropancreatic neuroendocrine tumours: an overview |journal=Br J Nurs |volume=25 |issue=4 |pages=S12–5 |date=2016 |pmid=26911175 |doi=10.12968/bjon.2016.25.4.S12 |url=}}</ref><ref name="pmid21311954">{{cite journal |vauthors=Oberg K, Castellano D |title=Current knowledge on diagnosis and staging of neuroendocrine tumors |journal=Cancer Metastasis Rev. |volume=30 Suppl 1 |issue= |pages=3–7 |date=March 2011 |pmid=21311954 |doi=10.1007/s10555-011-9292-1 |url=}}</ref> | ||
*[[Midgut]] [[gastrointestinal]] tract NETs (GINETs) produce [[serotonin]] and other [[vasoactive]] [[substances]] that give rise to the typical [[carcinoid]] [[syndrome]]. | *[[Midgut]] [[gastrointestinal]] tract NETs (GINETs) produce [[serotonin]] and other [[vasoactive]] [[substances]] that give rise to the typical [[carcinoid]] [[syndrome]]. | ||
*[[Lung]] [[neuroendocrine tumors]] produce lesser quantities of [[serotonin]]. | |||
*[[carcinoid syndrome]] is caused less commonly by [[lung]] [[neuroendocrine tumor]] and most often with [[tumors]] of large [[size]] (>5 cm). | |||
Revision as of 14:32, 22 April 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Anum Gull M.B.B.S.[2]Parminder Dhingra, M.D. [3]
Overview
Gastroenteropancreatic neuroendocrine tumors are classified based upon their origin from the embryonic divisions of the alimentary tract into foregut (bronchial, stomach), midgut (small intestine, appendix, cecum) and hindgut (distal colon, rectum, genitourinary) tumours.
Classification
- Gastroenteropancreatic neuroendocrine tumors are classified based upon their origin from the embryonic divisions of the alimentary tract:
- Foregut (bronchial, stomach)
- Midgut (small intestine, appendix, cecum)
- Hindgut (distal colon, rectum, genitourinary)
- GET-NETs produce a number of secretory products, resulting in a wide range of clinical symptoms.[1] [2][3]
- Midgut gastrointestinal tract NETs (GINETs) produce serotonin and other vasoactive substances that give rise to the typical carcinoid syndrome.
- Lung neuroendocrine tumors produce lesser quantities of serotonin.
- carcinoid syndrome is caused less commonly by lung neuroendocrine tumor and most often with tumors of large size (>5 cm).
|
Carcinoid syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Carcinoid syndrome classification On the Web |
|
American Roentgen Ray Society Images of Carcinoid syndrome classification |
|
Risk calculators and risk factors for Carcinoid syndrome classification |
| Foregut | Midgut | Hindgut | |
|---|---|---|---|
| Location | |||
| Hormones produced | Variable | ||
| Possibility of carcinoid syndrome | Rare, and atypical when it happens | Classic | Rare |
References
- ↑ Büyükaşık K, Arı A, Tatar C, Akçe B, Sevinç MM, Sarı S, Paşaoğlu E, Bektaş H (2017). "Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases". Turk J Surg. 33 (4): 279–283. doi:10.5152/UCD.2017.3685. PMID 29260133.
- ↑ Davies L, Weickert MO (2016). "Gastroenteropancreatic neuroendocrine tumours: an overview". Br J Nurs. 25 (4): S12–5. doi:10.12968/bjon.2016.25.4.S12. PMID 26911175.
- ↑ Oberg K, Castellano D (March 2011). "Current knowledge on diagnosis and staging of neuroendocrine tumors". Cancer Metastasis Rev. 30 Suppl 1: 3–7. doi:10.1007/s10555-011-9292-1. PMID 21311954.